SMA
SUPN icon

Sage Mountain Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Sage Mountain Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-574
Closed -$15K – 702
2021
Q3 		$15K Hold
574
– – ﹤0.01% 556
2021
Q2 		$18K Hold
574
– – ﹤0.01% 505
2021
Q1 		$15K Buy
+574
New +$16.1K ﹤0.01% 437

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Sage Mountain Advisors's SUPN Position: Q4 2021 in Review

Sage Mountain Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 574 shares — an estimated $15K sold.

Sage Mountain Advisors first reported a position in SUPN in Q1 2021 and held it in 3 quarters. The position peaked at $18K in Q2 2021. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

  • Sage Mountain Advisors reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sage Mountain Advisors sold 574 Supernus Pharmaceuticals shares in Q4 2021, an estimated $15K.
  • Sage Mountain Advisors first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Sage Mountain Advisors's Supernus Pharmaceuticals position peaked at $18K in Q2 2021.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Sage Mountain Advisors's 13F filing for Q4 2021, filed 2 Feb 2022.